Cited by 2,527Lung Cancer Treatments and MutationsLung Cancer Research StudiesLung Cancer Diagnosis and Treatment

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

Alectinib versus Crizotinib in Untreated ALK -Positive Non–Small-Cell Lung Cancer

Open access

Peters, Solange, Camidge, D. Ross, Shaw, Alice T., Gadgeel, Shirish, Ahn, Jin S., Kim, Dong-Wan, Ou, Sai-Hong I., Pérol, Maurice, Dziadziuszko, Rafal, Rosell, Rafael, Zeaiter, Ali, Mitry, Emmanuel, Golding, Sophie, Balas, Bogdana, Noe, Johannes, Morcos, Peter N., Mok, Tony·2017·New England Journal of Medicine

DOI 10.1056/nejmoa1704795

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Alectinib, a highly selective inhibitor of anaplastic lymphoma kinase (ALK), has shown systemic and central nervous system (CNS) efficacy in the treatment of ALK-positive non-small-cell lung cancer (NSCLC). We investigated alectinib as compared with crizotinib in patients with previously untreated, advanced ALK-positive NSCLC, including those with asymptomatic CNS disease. METHODS: In a randomized, open-label, phase 3 trial, we randomly assigned 303 patients with previously untreated, advanced ALK-positive NSCLC to receive either alectinib (600 mg twice daily) or crizotinib (250 mg twice daily). The primary end point was investigator-assessed progression-free survival. Secondary end points were independent review committee-assessed progression-free survival, time to CNS progression, objective response rate, and overall survival. RESULTS: During a median follow-up of 17.6 months (crizotinib) and 18.6 months (alectinib), an event of disease progression or death occurred in 62 of 152 patients (41%) in the alectinib group and 102 of 151 patients (68%) in the crizotinib group. The rate of investigator-assessed progression-free survival was significantly higher with alectinib than with crizotinib (12-month event-free survival rate, 68.4% [95% confidence interval (CI), 61.0 to 75.9] with alectinib vs. 48.7% [95% CI, 40.4 to 56.9] with crizotinib; hazard ratio for disease progression or death, 0.47 [95% CI, 0.34 to 0.65]; P<0.001); the median progression-free survival with alectinib was not reached. The results for independent review committee-assessed progression-free survival were consistent with those for the primary end point. A total of 18 patients (12%) in the alectinib group had an event of CNS progression, as compared with 68 patients (45%) in the crizotinib group (cause-specific hazard ratio, 0.16; 95% CI, 0.10 to 0.28; P<0.001). A response occurred in 126 patients in the alectinib group (response rate, 82.9%; 95% CI, 76.0 to 88.5) and in 114 patients in the crizotinib group (response rate, 75.5%; 95% CI, 67.8 to 82.1) (P=0.09). Grade 3 to 5 adverse events were less frequent with alectinib (41% vs. 50% with crizotinib). CONCLUSIONS: As compared with crizotinib, alectinib showed superior efficacy and lower toxicity in primary treatment of ALK-positive NSCLC. (Funded by F. Hoffmann-La Roche; ALEX ClinicalTrials.gov number, NCT02075840 .).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmoa1704795

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

First-Line Crizotinib versus Chemotherapy in ALK -Positive Lung Cancer
Solomon, B. J., Mok, T., Kim, D.-W., Wu, Y.-L., Nakagawa, K., Mekhail, T., Felip, E., Cappuzzo, F., Paolini, J., Usari, T., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1408440 · Cited by 3,190
Self-citation
Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK -Rearranged Lung Cancer
Gainor, J. F., Dardaei, L., Yoda, S., Friboulet, L., Leshchiner, I., Katayama, R., Dagogo‐Jack, I., Gadgeel, S. M., Schultz, K. R., Singh, M., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0596 · Cited by 1,180
Self-citation
First-line ceritinib versus platinum-based chemotherapy in advanced ALK -rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study
Soria, J.-C., Tan, D. S. W., Chiari, R., Wu, Y.-L., Paz-Ares, L., Wolf, J., Geater, S. L., Orlov, S., Cortinovis, D., Yu, C.-J., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30123-x · Cited by 1,151
Alectinib versus crizotinib in patients with ALK -positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial
Hida, T., Nokihara, H., Kondo, M., Kim, Y. H., Azuma, K., Seto, T., Takiguchi, Y., Nishio, M., Yoshioka, H., Imamura, F., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30565-2 · Cited by 935
Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study
Gadgeel, S. M., Gandhi, L., Riely, G. J., Chiappori, A., West, H., Azada, M. C., Morcos, P. N., Lee, R.-M., Garcia, L., Yu, L. J., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70362-6 · Cited by 709
Self-citation
Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial
Shaw, A. T., Gandhi, L., Gadgeel, S., Riely, G. J., Cetnar, J., West, H., Camidge, D. R., Socinski, M. A., Chiappori, A., Mekhail, T., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00488-x · Cited by 638
Self-citation
Alectinib in Crizotinib-Refractory ALK-Rearranged Non–Small-Cell Lung Cancer: A Phase II Global Study
Ou, S. I., Ahn, J. S., Petris, L. D., Govindan, R., Yang, J. C., Hughes, B. G. M., Léna, H., Moro‐Sibilot, D., Bearz, A., Viteri, S., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.9443 · Cited by 592
Self-citation
Brain metastases in patients with EGFR -mutated or ALK -rearranged non-small-cell lung cancers
Rangachari, D., Yamaguchi, N., VanderLaan, P. A., Folch, E. E., Mahadevan, A., Floyd, S., Uhlmann, E. J., Wong, E. T., Dahlberg, S. E., Huberman, M. S., et al. (2015) · Lung Cancer · doi:10.1016/j.lungcan.2015.01.020 · Cited by 547
Therapeutic Targeting of Anaplastic Lymphoma Kinase in Lung Cancer: A Paradigm for Precision Cancer Medicine
Katayama, R., Lovly, C. M., & Shaw, A. T. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2791 · Cited by 265
Self-citation
ALK inhibitors in non-small cell lung cancer: crizotinib and beyond.
Awad, M. M., & Shaw, A. T. (2014) · PubMed · Cited by 245
Self-citation

Flagged first, then by citations

Show all 14 references

Research works printed but not linked: 3

Awad MM, 2014, Clin Adv Hematol Oncol, 12, 429
Lu S, 2016, J Clin Oncol
Hida T, Lancet

Sorted by citations

Items 301–400 of 1,000

Tyrosine Kinase Inhibitors With and Without Up-Front Stereotactic Radiosurgery for Brain Metastases From EGFR and ALK Oncogene–Driven Non–Small Cell Lung Cancer (TURBO-NSCLC)
Pike, L., Miao, E., Boe, L. A., Patil, T., Imber, B. S., Myall, N. J., Pollom, E. L., Hui, C., Qu, V., Langston, J., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.23.02668 · Cited by 59
Self-citation
Stereotactic Radiosurgery for Multiple Brain Metastases
Kraft, J., Zindler, J. D., Minniti, G. C., Gückenberger, M., & Andratschke, N. H. (2019) · Current Treatment Options in Neurology · doi:10.1007/s11940-019-0548-3 · Cited by 58
The Landscape of Actionable Gene Fusions in Colorectal Cancer
Pagani, F., Randon, G., Guarini, V., Raimondi, A., Prisciandaro, M., Lobefaro, R., Bartolomeo, M. D., Sozzi, G., de Braud, F., Gasparini, P., et al. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20215319 · Cited by 58
Exon 20 YVMA insertion is associated with high incidence of brain metastasis and inferior outcome of chemotherapy in advanced non-small cell lung cancer patients with HER2 kinase domain mutations
Yang, S., Wang, Y., Zhao, C., Li, X., Liu, Q., Mao, S., Liu, Y., Yu, X., Wang, W., Tian, Q., et al. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-559 · Cited by 60
Diagnostic Value and Cost-Effectiveness of Next-Generation Sequencing–Based Testing for Treatment of Patients with Advanced/Metastatic Non-Squamous Non–Small-Cell Lung Cancer in the United States
Zou, D., Ye, W., Hess, L. M., Bhandari, N. R., Ale-Ali, A., Foster, J., Quon, P., & Harris, M. (2022) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2022.04.010 · Cited by 57
Translocation Renal Cell Carcinoma: An Update on Clinicopathological and Molecular Features
Inamura, K. (2017) · Cancers · doi:10.3390/cancers9090111 · Cited by 58
Phase II study of ceritinib in alectinib‐pretreated patients with anaplastic lymphoma kinase‐rearranged metastatic non‐small‐cell lung cancer in Japan: ASCEND ‐9
Hida, T., Seto, T., Horinouchi, H., Maemondo, M., Takeda, M., Hotta, K., Hirai, F., Kim, Y. H., Matsumoto, S., Ito, M., et al. (2018) · Cancer Science · doi:10.1111/cas.13721 · Cited by 57
Brain Metastases in Non-Small-Cell Lung Cancer: Are Tyrosine Kinase Inhibitors and Checkpoint Inhibitors Now Viable Options?
Abdallah, S. M.-B., & Wong, A. N. M. (2018) · Current Oncology · doi:10.3747/co.25.3733 · Cited by 57
Translocation-Related Sarcomas
Nakano, K., & Takahashi, S. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19123784 · Cited by 60
Management of oligometastatic non-small cell lung cancer patients: Current controversies and future directions
Couñago, F., Luna, J., Guerrero, L. L., Barrón, B. V., Guillen-Sacoto, M. C., González-Merino, T., Taboada, B., Díaz, V. D., Rubio‐Viqueira, B., Díaz-Gavela, A. A., et al. (2019) · World Journal of Clinical Oncology · doi:10.5306/wjco.v10.i10.318 · Cited by 57
Alectinib: A Review in Advanced, ALK-Positive NSCLC
Paik, J., & Dhillon, S. (2018) · Drugs · doi:10.1007/s40265-018-0952-0 · Cited by 56
ALK Mutation Status Before and After Alectinib Treatment in Locally Advanced or Metastatic ALK-Positive NSCLC: Pooled Analysis of Two Prospective Trials
Noé, J., Lovejoy, A., Ou, S. I., Yaung, S. J., Bordogna, W., Klass, D. M., Cummings, C. A., & Shaw, A. T. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.10.015 · Cited by 56
Self-citation
New Target Therapies in Advanced Non-Small Cell Lung Cancer: A Review of the Literature and Future Perspectives
de Mello, R. A., Neves, N. M., Tadokoro, H., Amaral, G. A., Castelo‐Branco, P., & Zia, V. A. D. A. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9113543 · Cited by 59
Targeting non-small cell lung cancer: driver mutation beyond epidermal growth factor mutation and anaplastic lymphoma kinase fusion
Chu, Q. S.-C. (2020) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835919895756 · Cited by 56
Rates of Guideline-Concordant Surgery and Adjuvant Chemotherapy Among Patients With Early-Stage Lung Cancer in the US ALCHEMIST Study (Alliance A151216)
Kehl, K. L., Zahrieh, D. M., Yang, P., Hillman, S. L., Tan, A. D., Sands, J. M., Oxnard, G. R., Gillaspie, E. A., Wigle, D. A., Malik, S. M., et al. (2022) · JAMA Oncology · doi:10.1001/jamaoncol.2022.0039 · Cited by 55
ALK fusion variants detection by targeted RNA-next generation sequencing and clinical responses to crizotinib in ALK-positive non-small cell lung cancer
Leer, A. M., Duruisseaux, M., Pinsolle, J., Dubourd, S., Mondet, J., Phillips-Houlbracq, M., Magnat, N., Fauré, J., Chatagnon, A., de Fraipont, F., et al. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.12.004 · Cited by 55
Immunotherapy combined with epidermal growth factor receptor-tyrosine kinase inhibitors in non-small-cell lung cancer treatment
Liang, H., Liu, X., & Wang, M. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s178497 · Cited by 55
CNS metastasis in ROS1+ NSCLC: An urgent call to action, to understand, and to overcome
Ou, S. I., & Zhu, V. W. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.02.025 · Cited by 55
Self-citation
Non-small cell lung cancer: Emerging molecular targeted and immunotherapeutic agents
Singh, T., Hassanabad, M. F., & Hassanabad, A. F. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188636 · Cited by 54
Cancer Drug Approvals That Displaced Existing Standard-of-Care Therapies, 2016-2021
Benjamin, D. J., Xu, A., Lythgoe, M. P., & Prasad, V. K. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.2265 · Cited by 54
Brain metastases in ALK-positive NSCLC - time to adjust current treatment algorithms
Griesinger, F., Roeper, J., Pöttgen, C., Willborn, K., & Eberhardt, W. (2018) · Oncotarget · doi:10.18632/oncotarget.26073 · Cited by 55
The deep learning model combining CT image and clinicopathological information for predicting ALK fusion status and response to ALK-TKI therapy in non-small cell lung cancer patients
Song, Z., Liu, T., Shi, L., Yu, Z., Shen, Q., Xu, M., Huang, Z., Cai, Z., Wang, W., Xu, C., et al. (2020) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-020-04986-6 · Cited by 55
New Generations of Tyrosine Kinase Inhibitors in Treating NSCLC with Oncogene Addiction: Strengths and Limitations
Attili, I., Corvaja, C., Spitaleri, G., Signore, E. D., Aliaga, P. T., Passaro, A., & de Marinis, F. (2023) · Cancers · doi:10.3390/cancers15205079 · Cited by 56
Update on cardio-oncology: Novel cancer therapeutics and associated cardiotoxicities
Guha, A., Armanious, M. A., & Fradley, M. G. (2018) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2018.06.001 · Cited by 54
Spotlight on lorlatinib and its potential in the treatment of NSCLC: the evidence to date
Akamine, T., Toyokawa, G., Tagawa, T., & Seto, T. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s165511 · Cited by 55
The incidence of ALK inhibitor-related pneumonitis in advanced non-small-cell lung cancer patients: A systematic review and meta-analysis
Suh, C. H., Kim, K. W., Pyo, J., Hatabu, H., & Nishino, M. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.04.015 · Cited by 55
OX40 and OX40L protein expression of tumor infiltrating lymphocytes in non-small cell lung cancer and its role in clinical outcome and relationships with other immune biomarkers
He, Y., Zhang, X., Jia, K., Dziadziuszko, R., Zhao, S., Deng, J., Wang, H., Hirsch, F. R., & Zhou, C. (2019) · Translational Lung Cancer Research · doi:10.21037/tlcr.2019.08.15 · Cited by 54
Self-citation
Large Cell Neuro-Endocrine Carcinoma of the Lung: Current Treatment Options and Potential Future Opportunities
Ferrara, M. G., Stefani, A., Simbolo, M., Pilotto, S., Martini, M., Lococo, F., Vita, E., Chiappetta, M., Cancellieri, A., D’Argento, E., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.650293 · Cited by 53
NVL-520 Is a Selective, TRK-Sparing, and Brain-Penetrant Inhibitor of ROS1 Fusions and Secondary Resistance Mutations
Drilon, A., Horan, J. C., Tangpeerachaikul, A., Besse, B., Ou, S.-H. I., Gadgeel, S. M., Camidge, D. R., van der Wekken, A. J., Nguyen-Phuong, L., Acker, A., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0968 · Cited by 52
Self-citation
Exposure–Response Analyses of Anaplastic Lymphoma Kinase Inhibitors Crizotinib and Alectinib in Non‐Small Cell Lung Cancer Patients
Groenland, S. L., Geel, D. R., Janssen, J. M., de Vries, N., Rosing, H., Beijnen, J. H., Burgers, J. A., Smit, E. F., Huitema, A. D. R., & Steeghs, N. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1989 · Cited by 52
Strategies to overcome resistance to ALK inhibitors in non-small cell lung cancer: a narrative review
Desai, A. P., & Lovly, C. M. (2023) · Translational Lung Cancer Research · doi:10.21037/tlcr-22-708 · Cited by 55
Histological transformation in lung adenocarcinoma: Insights of mechanisms and therapeutic windows
Tan, N., Li, Y., Ying, J., & Chen, W. (2024) · Journal of Translational Internal Medicine · doi:10.1515/jtim-2024-0019 · Cited by 52
Precision medicine in ALK rearranged NSCLC: A rapidly evolving scenario
Addeo, A., Tabbò, F., Robinson, T., Buffoni, L., & Novello, S. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.12.015 · Cited by 52
Efficacy of ALK inhibitors on NSCLC brain metastases: A systematic review and pooled analysis of 21 studies
Petrelli, F., Lazzari, C., Ardito, R., Borgonovo, K., Bulotta, A., Conti, B., Cabiddu, M., Capitanio, J. F., Brighenti, M., Ghilardi, M., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0201425 · Cited by 52
Highly sensitive fusion detection using plasma cell‐free RNA in non‐small‐cell lung cancers
Hasegawa, N., Kohsaka, S., Kurokawa, K., Shinno, Y., Nakamura, I. T., Ueno, T., Kojima, S., Kawazu, M., Suehara, Y., Ishijima, M., et al. (2021) · Cancer Science · doi:10.1111/cas.15084 · Cited by 52
ASCEND-7: Efficacy and Safety of Ceritinib Treatment in Patients with ALK -Positive Non–Small Cell Lung Cancer Metastatic to the Brain and/or Leptomeninges
Chow, L. Q. M., Barlési, F., Bertino, E. M., van den Bent, M. J., Wakelee, H. A., Wen, P. Y., Chiu, C.-H., Orlov, S., Chiari, R., Majem, M., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1838 · Cited by 53
Self-citation
Therapeutic Sequencing in ALK+ NSCLC
Elsayed, M., & Christopoulos, P. (2021) · Pharmaceuticals · doi:10.3390/ph14020080 · Cited by 52
Biological and Genetic Mechanisms of COPD, Its Diagnosis, Treatment, and Relationship with Lung Cancer
Czarnecka, K. H., Mukherjee, D., Maryanchik, S. V., & Rudzińska, M. (2023) · Biomedicines · doi:10.3390/biomedicines11020448 · Cited by 51
ALK Inhibitors, Resistance Development, Clinical Trials
Rothenstein, J. M., & Chooback, N. (2018) · Current Oncology · doi:10.3747/co.25.3760 · Cited by 51
Altered editing level of microRNAs is a potential biomarker in lung adenocarcinoma
Maemura, K., Watanabe, K., Ando, T., Hiyama, N., Sakatani, T., Amano, Y., Kage, H., Nakajima, J., Yatomi, Y., Nagase, T., et al. (2018) · Cancer Science · doi:10.1111/cas.13742 · Cited by 51
Efficacy of Alectinib in Patients with ALK-Positive NSCLC and Symptomatic or Large CNS Metastases
Lin, J. J., Jiang, G. Y., Joshipura, N. D., Ackil, J., Digumarthy, S. R., Rincon, S., Yeap, B. Y., Gainor, J. F., & Shaw, A. T. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.12.002 · Cited by 52
Self-citation
ALK rearrangements: Biology, detection and opportunities of therapy in non-small cell lung cancer
Rosas, G., Ruiz, R., Araujo, J. M., Pinto, J. A., & Mas, L. A. (2019) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2019.02.006 · Cited by 53
Patient-reported outcomes from the randomized phase III ALEX study of alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer
Pérol, M., Pavlakis, N., Levchenko, E., Platania, M., Oliveira, J., Novello, S., Chiari, R., Morán, T., Mitry, E., Nüesch, E., et al. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.10.002 · Cited by 52
Self-citation
SOX13 promotes colorectal cancer metastasis by transactivating SNAI2 and c-MET
Du, F., Li, X., Feng, W., Qiao, C., Chen, J., Jiang, M., Qiu, Z., Qian, M., Tian, D., Nie, Y., et al. (2020) · Oncogene · doi:10.1038/s41388-020-1233-4 · Cited by 51
Multidisciplinary patient-centered management of brain metastases and future directions
Palmer, J. D., Trifiletti, D. M., Gondi, V., Chan, M. D., Minniti, G. C., Rusthoven, C. G., Schild, S. E., Mishra, M. V., Bovi, J. A., Williams, N. O., et al. (2020) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdaa034 · Cited by 52
Clinical Relevance of an Amplicon-Based Liquid Biopsy for DetectingALKandROS1Fusion and Resistance Mutations in Patients With Non–Small-Cell Lung Cancer
Mezquita, L., Swalduz, A., Jovelet, C., Ortiz‐Cuaran, S., Howarth, K., Planchard, D., Avrillon, V., Recondo, G., Marteau, S., Benítez, J. C., et al. (2020) · JCO Precision Oncology · doi:10.1200/po.19.00281 · Cited by 51
Will the clinical development of 4th-generation “double mutant active” ALK TKIs (TPX-0131 and NVL-655) change the future treatment paradigm of ALK+ NSCLC?
Ou, S. I., Nagasaka, M., Brazel, D., Hou, Y., & Zhu, V. W. (2021) · Translational Oncology · doi:10.1016/j.tranon.2021.101191 · Cited by 52
Self-citation
The efficacy and safety of ALK inhibitors in the treatment of ALK ‐positive non‐small cell lung cancer: A network meta‐analysis
Fan, J., Fong, T. H., Xia, Z., Zhang, J., & Luo, P. (2018) · Cancer Medicine · doi:10.1002/cam4.1768 · Cited by 50
Druggable targets meet oncogenic drivers: opportunities and limitations of target-based classification of tumors and the role of Molecular Tumor Boards
Danesi, R., Fogli, S., Indraccolo, S., Re, M. D., Tos, A. P. D., Leoncini, L., Antonuzzo, L., Bonanno, L., Guarneri, V., Pierini, A., et al. (2021) · ESMO Open · doi:10.1016/j.esmoop.2020.100040 · Cited by 52
Management of brain metastases in lung cancer: evolving roles for radiation and systemic treatment in the era of targeted and immune therapies
Myall, N. J., Yu, H. A., Soltys, S. G., Wakelee, H. A., & Pollom, E. L. (2021) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdab106 · Cited by 54
Circulating Cell-free DNA as a Prognostic Biomarker in Patients with Advanced ALK + Non–small Cell Lung Cancer in the Global Phase III ALEX Trial
Dziadziuszko, R., Peters, S., Mok, T., Camidge, D. R., Gadgeel, S. M., Ou, S.-H. I., Konopa, K., Noé, J., Nowicka, M., Bordogna, W., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-2840 · Cited by 50
Self-citation
Multi-target tyrosine kinase inhibitor nanoparticle delivery systems for cancer therapy
Xu, W., Ye, C., Qing, X., Liu, S., Lv, X., Wang, W., Dong, X., & Zhang, Y. (2022) · Materials Today Bio · doi:10.1016/j.mtbio.2022.100358 · Cited by 51
Making the Rounds: Exploring the Role of Circulating Tumor DNA (ctDNA) in Non-Small Cell Lung Cancer
Shields, M. D., Chen, K., Dutcher, G., Patel, I., & Pellini, B. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23169006 · Cited by 51
Phase I Trial of Targeted EGFR or ALK Therapy with Ipilimumab in Metastatic NSCLC with Long-Term Follow-Up
Chalmers, A. W., Patel, S. B., Boucher, K. M., Cannon, L. A., Esplin, M., Luckart, J. B., Graves, N., Duren, T. V., & Akerley, W. (2019) · Targeted Oncology · doi:10.1007/s11523-019-00658-0 · Cited by 50
American Radium Society Appropriate Use Criteria for Radiation Therapy in Oligometastatic or Oligoprogressive Non-Small Cell Lung Cancer
Amini, A., Verma, V., Simone, C. B., Chetty, I. J., Chun, S. G., Donington, J. S., Edelman, M. J., Higgins, K. A., Kestin, L. L., Movsas, B., et al. (2021) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2021.09.022 · Cited by 50
Lorlatinib in pretreated ALK- or ROS1-positive lung cancer and impact of TP53 co-mutations: results from the German early access program
Frost, N., Christopoulos, P., Kauffmann-Guerrero, D. E., Stratmann, J., Riedel, R. F., Schaefer, M., Alt, J. A., Gutz, S., Christoph, D. C., Laack, E., et al. (2021) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920980558 · Cited by 49
Progress in the Management of Advanced Thoracic Malignancies in 2017
Ferrara, R., Mezquita, L., & Besse, B. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.01.002 · Cited by 50
Immunotherapy for oncogenic-driven advanced non-small cell lung cancers: Is the time ripe for a change?
Remón, J., Hendriks, L. E. L., Cabrera, C., Reguart, N., & Besse, B. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.10.006 · Cited by 49
Precision oncology: separating the wheat from the chaff
Remón, J., & Dienstmann, R. (2018) · ESMO Open · doi:10.1136/esmoopen-2018-000446 · Cited by 49
Alectinib in the treatment of ALK-positive metastatic non-small cell lung cancer: clinical trial evidence and experience with a focus on brain metastases
Tomasini, P., Egea, J., Souquet-Bressand, M., Greillier, L., & Barlési, F. (2019) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753466619831906 · Cited by 54
How I treat ALK-positive non-small cell lung cancer
McCusker, M. G., Russo, A., Scilla, K. A., Mehra, R., & Rolfo, C. D. (2019) · ESMO Open · doi:10.1136/esmoopen-2019-000524 · Cited by 49
Medical management of brain metastases
Lauko, A. J., Rauf, Y., & Ahluwalia, M. S. (2020) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdaa015 · Cited by 51
Characterization of a Real-World Response Variable and Comparison with RECIST-Based Response Rates from Clinical Trials in Advanced NSCLC
Ma, X., Bellomo, L. P., Magee, K., Bennette, C. S., Tymejczyk, O., Samant, M. K., Tucker, M., Nussbaum, N. C., Bowser, B. E., Kraut, J. S., et al. (2021) · Advances in Therapy · doi:10.1007/s12325-021-01659-0 · Cited by 49
Structure-based discovery of SIAIS001 as an oral bioavailability ALK degrader constructed from Alectinib
Ren, C., Sun, N., Kong, Y., Qu, X., Liu, H., Zhong, H., Song, X., Yang, X., & Jiang, B. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113335 · Cited by 50
Lorlatinib Should Not be Considered as the Preferred First-Line Option in Patients With Advanced ALK Rearranged NSCLC
Camidge, D. R. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.12.022 · Cited by 49
Self-citation
Toward a More Precise Future for Oncology
Murciano-Goroff, Y. R., Taylor, B. S., Hyman, D. M., & Schram, A. M. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.03.014 · Cited by 48
Personalised medicine for nonsmall cell lung cancer
Mascaux, C., Tomasini, P., Greillier, L., & Barlési, F. (2017) · European Respiratory Review · doi:10.1183/16000617.0066-2017 · Cited by 49
Alectinib Resistance in ALK-Rearranged Lung Cancer by Dual Salvage Signaling in a Clinically Paired Resistance Model
Tsuji, T., Ozasa, H., Aoki, W., Aburaya, S., Funazo, T. Y., Furugaki, K., Yoshimura, Y., Ajimizu, H., Okutani, R., Yasuda, Y., et al. (2018) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-18-0325 · Cited by 48
Drug resistance mechanisms in Japanese anaplastic lymphoma kinase‐positive non–small cell lung cancer and the clinical responses based on the resistant mechanisms
Yanagitani, N., Uchibori, K., Koike, S., Tsukahara, M., Kitazono, S., Yoshizawa, T., Horiike, A., Ohyanagi, F., Tambo, Y., Nishikawa, S., et al. (2020) · Cancer Science · doi:10.1111/cas.14314 · Cited by 48
Canadian Consensus: Oligoprogressive, Pseudoprogressive, and Oligometastatic Non-Small-Cell Lung Cancer
Laurie, S. A., Banerji, S. O., Blais, N., Brule, S. Y., Cheema, P. K., Cheung, P., Daaboul, N., Hao, D., Hirsh, V., Juergens, R. A., et al. (2019) · Current Oncology · doi:10.3747/co.26.4116 · Cited by 48
ALK peptide vaccination restores the immunogenicity of ALK-rearranged non-small cell lung cancer
Mota, I. A., Patrucco, E., Mastini, C., Mahadevan, N. R., Thai, T. C., Bergaggio, E., Cheong, T.-C., Leonardi, G. C., Atabay, E. K., Campisi, M., et al. (2023) · Nature Cancer · doi:10.1038/s43018-023-00591-2 · Cited by 47
Unraveling the Potential of ALK-Targeted Therapies in Non-Small Cell Lung Cancer: Comprehensive Insights and Future Directions
Parvaresh, H., Roozitalab, G., Golandam, F., Behzadi, P., & Kaboli, P. J. (2024) · Biomedicines · doi:10.3390/biomedicines12020297 · Cited by 48
Management of brain metastases in non-small cell lung cancer in the era of tyrosine kinase inhibitors
Wrona, A., Dziadziuszko, R., & Jassem, J. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.10.011 · Cited by 48
Self-citation
A user’s guide to lorlatinib
Nagasaka, M., Ge, Y., Sukari, A. W., Kukreja, G., & Ou, S. I. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.102969 · Cited by 49
Self-citation
The Role of Malnutrition and Muscle Wasting in Advanced Lung Cancer
Jain, R., Coss, C. C., Whooley, P. D., Phelps, M. A., & Owen, D. H. (2020) · Current Oncology Reports · doi:10.1007/s11912-020-00916-9 · Cited by 47
Targetable gene fusions and aberrations in genitourinary oncology
Pederzoli, F., Bandini, M., Marandino, L., Ali, S. M., Madison, R. W., Chung, J., Ross, J. S., & Necchi, A. (2020) · Nature Reviews Urology · doi:10.1038/s41585-020-00379-4 · Cited by 49
Intracranial efficacy of alectinib in ALK-positive NSCLC patients with CNS metastases—a multicenter retrospective study
Zou, Z., Xing, P., Hao, X., Wang, Y., Song, X., Li, S., Zhang, C., Liu, Z., Ma, K., Dong, G., et al. (2022) · BMC Medicine · doi:10.1186/s12916-021-02207-x · Cited by 49
Efficacy and Safety of Brigatinib Compared With Crizotinib in Asian vs. Non-Asian Patients With Locally Advanced or Metastatic ALK–Inhibitor-Naive ALK+ Non–Small Cell Lung Cancer: Final Results From the Phase III ALTA-1L Study
Ahn, M., Kim, H. R., Yang, J. C., Han, J.-Y., Li, J. Y.-C., Hochmair, M. J., Chang, G.-C., Delmonte, A., Lee, K. H., Campelo, R. G., et al. (2022) · Clinical Lung Cancer · doi:10.1016/j.cllc.2022.07.008 · Cited by 47
Self-citation
Prognostic and predictive biomarkers in non-small cell lung carcinoma
Odintsov, I., & Sholl, L. M. (2023) · Pathology · doi:10.1016/j.pathol.2023.11.006 · Cited by 47
Iruplinalkib (WX-0593) Versus Crizotinib in ALK TKI-Naive Locally Advanced or Metastatic ALK-Positive NSCLC: Interim Analysis of a Randomized, Open-Label, Phase 3 Study (INSPIRE)
Shi, Y., Chen, J., Yang, R., Wu, H., Wang, Z., Yang, W., Cui, J., Zhang, Y., Liu, C., Cheng, Y., et al. (2024) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2024.01.013 · Cited by 46
Non-small cell lung cancer treatment (r)evolution: ten years of advances and more to come
Toschi, L., Rossi, S., Finocchiaro, G., & Santoro, A. (2017) · ecancermedicalscience · doi:10.3332/ecancer.2017.787 · Cited by 48
ALK (D5F3) CDx: an immunohistochemistry assay to identify ALK-positive NSCLC patients
Uruga, H., & Mino-Kenudson, M. A. (2018) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s156672 · Cited by 46
ALK Testing Trends and Patterns Among Community Practices in the United States
Illei, P. B., Wong, W. B., Wu, N., Chu, L. K., Gupta, R., Schulze, K., & Gubens, M. A. (2018) · JCO Precision Oncology · doi:10.1200/po.18.00159 · Cited by 46
Implementing a comprehensive translational oncology platform: from molecular testing to actionability
Mitri, Z. I., Parmar, S. S., Johnson, B., Kolodzie, A., Keck, J. M., Morris, M., Guimarães, A. R., Beckett, B. R., Borate, U., Lopez, C. D., et al. (2018) · Journal of Translational Medicine · doi:10.1186/s12967-018-1733-y · Cited by 46
Efficacy of Immune Checkpoint Inhibitor Monotherapy for Advanced Non-Small-Cell Lung Cancer with ALK Rearrangement
Oya, Y., Kuroda, H., Nakada, T., Takahashi, Y., Sakakura, N., & Hida, T. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21072623 · Cited by 46
Treatment of advanced non-small-cell lung cancer
Prabhash, K., Vora, A. D., Limaye, S. A., Sahoo, T. P., Batra, U., Patil, S., Patil, V., Noronha, V., Bhosale, B., Raut, N. V., et al. (2021) · Cancer Research Statistics and Treatment · doi:10.4103/crst.crst_61_21 · Cited by 46
The Pan-Immune-Inflammation Value predicts the survival of patients with anaplastic lymphoma kinase-positive non-small cell lung cancer treated with first-line ALK inhibitor
Chen, X., Hong, X., Chen, G., Xue, J., Huang, J., Wang, F., Ali, W. A. S., Li, J., & Zhang, L. (2022) · Translational Oncology · doi:10.1016/j.tranon.2021.101338 · Cited by 46
Final efficacy and safety data, and exploratory molecular profiling from the phase III ALUR study of alectinib versus chemotherapy in crizotinib-pretreated ALK-positive non-small-cell lung cancer
Wolf, J. M., Helland, Å., Oh, I., Migliorino, M. R., Dziadziuszko, R., Wrona, A., de Castro, J., Mazières, J., Griesinger, F., Chlistalla, M., et al. (2022) · ESMO Open · doi:10.1016/j.esmoop.2021.100333 · Cited by 45
Self-citation
Cancer of the Lung
Araujo, L. H., Horn, L., Merritt, R. E., Shilo, K., Xu‐Welliver, M., & Carbone, D. P. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-47674-4.00069-4 · Cited by 47
ALK in cancer: from function to therapeutic targeting
Voena, C., Ambrogio, C., Iannelli, F., & Chiarle, R. (2025) · Nature reviews. Cancer · doi:10.1038/s41568-025-00797-9 · Cited by 49
Next-Generation Sequencing: A Review of Its Transformative Impact on Cancer Diagnosis, Treatment, and Resistance Management
Isaic, A., Motofelea, N., Hoinoiu, T., Motofelea, A. C., Leancu, I. C., Stan, E., Gheorghe, S. R., Duţu, A., & Crintea, A. (2025) · Diagnostics · doi:10.3390/diagnostics15192425 · Cited by 50
Advanced Non–Small Cell Lung Cancer: Sequencing Agents in the EGFR-Mutated/ALK-Rearranged Populations
Singhi, E. K., Horn, L., Sequist, L. V. D., Heymach, J. V., & Langer, C. J. (2019) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_237821 · Cited by 46
Frontiers of ctDNA, targeted therapies, and immunotherapy in non-small-cell lung cancer
Zhu, C., Zhuang, W., Chen, L., Yang, W., & Ou, W. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr.2020.01.09 · Cited by 46
BRAF V600E mutation and MET amplification as resistance pathways of the second-generation anaplastic lymphoma kinase (ALK) inhibitor alectinib in lung cancer
Shi, R., Filho, S. N. M., Li, M., Fares, A. F., Weiss, J., Pham, N., Ludkovski, O., Raghavan, V., Li, Q., Ravi, D., et al. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.05.018 · Cited by 45
Real-world evidence of the intrinsic limitations of PCR-based EGFR mutation assay in non-small cell lung cancer
Shen, C., Chiang, C., Shiao, T., Luo, Y., Chao, H., Huang, H.-C., & Chiu, C. (2022) · Scientific Reports · doi:10.1038/s41598-022-17394-7 · Cited by 47
Response to Selective RET Inhibition With LOXO-292 in a Patient With RET Fusion-Positive Lung Cancer With Leptomeningeal Metastases
Guo, R., Schreyer, M., Chang, J. C., Rothenberg, S. M., Henry, D., Cotzia, P., Kris, M. G., Rekhtman, N., Young, R. J., Hyman, D. M., et al. (2019) · JCO Precision Oncology · doi:10.1200/po.19.00021 · Cited by 44
Update of Diagnosis and Targeted Therapy for ALK+ Inflammation Myofibroblastic Tumor
Wang, Q., Chen, H., Wu, R., & Wu, C. (2023) · Current Treatment Options in Oncology · doi:10.1007/s11864-023-01144-6 · Cited by 45
Incidence, predictors and prognostic significance of thromboembolic disease in patients with advancedALK-rearranged non-small cell lung cancer
Zugazagoitia, J., Biosca, M., Oliveira, J., Olmedo, M. E., Dómine, M., Nadal, E., Ruffinelli, J. C., Muñoz, N., Luna, A. M., Hernández, B., et al. (2018) · European Respiratory Journal · doi:10.1183/13993003.02431-2017 · Cited by 44
ALK-rearrangement neuroendocrine carcinoma of the lung: a comprehensive study of a rare case series and review of literature
Zheng, Q., Zheng, M., Jin, Y., Shen, X., Shan, L., Shen, L., Sun, Y., Chen, H., & Li, Y. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s172124 · Cited by 46
Impact of pre-existing cardiovascular disease on treatment patterns and survival outcomes in patients with lung cancer
Batra, A., Sheka, D., Kong, S., & Cheung, W. Y. (2020) · BMC Cancer · doi:10.1186/s12885-020-07487-9 · Cited by 44

Authors: Peters, S., Camidge, D. R., Shaw, A. T., Gadgeel, S., Ahn, J. S., Kim, D.-W., Ou, S.-H. I., Pérol, M., Dziadziuszko, R., Rosell, R., Zeaiter, A., Mitry, E., Golding, S., Balas, B., Noe, J., Morcos, P. N., & Mok, T.
Affiliations: F. Hoffmann-La Roche AG (CH)
ORCID: Peters, Solange
Camidge, D. Ross
Shaw, Alice T.
Gadgeel, Shirish
Ahn, Jin S.
Kim, Dong-Wan
Ou, Sai-Hong I.
Rosell, Rafael
Mitry, Emmanuel
Balas, Bogdana
Morcos, Peter N.
Mok, Tony
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2017-08-31
Volume: 377
Issue: 9
Pages: 829-838
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa1704795
OpenAlex: W2624310346
Cited by: 2,527
References: 14
Citations by year: 2026: 173 · 2025: 216 · 2024: 260 · 2023: 270 · 2022: 306 · 2021: 336 · 2020: 327 · 2019: 276 · 2018: 277 · 2017: 82
FWCI: 218.03
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
SERVAL (Université de Lausanne) (publishedVersion, other-oa)
Dipòsit Digital de Documents de la UAB (Universitat Autònoma de Barcelona) (submittedVersion, public-domain)
IRIS (submittedVersion)
LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, public-domain)
Seoul National University Open Repository (Seoul National University) (submittedVersion)
Funders: Amgen
Bristol-Myers Squibb
Eli Lilly and Company
Pfizer
AstraZeneca
Ariad Pharmaceuticals
Celgene
F. Hoffmann-La Roche
Array BioPharma
Regeneron Pharmaceuticals
Taiho Pharmaceutical
Les Laboratories Pierre Fabre
Clovis Oncology
G1 Therapeutics
Eisai
Genentech
EMD Serono
Ignyta
Loxo Oncology
Foundation Medicine
Daiichi Sankyo Europe
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
Keywords: alectinib, crizotinib, anaplastic lymphoma kinase, ALK-positive non-small cell lung cancer, ALK inhibitors, progression-free survival, CNS progression, central nervous system metastasis, objective response rate, overall survival, first-line therapy, targeted therapy, head-to-head comparison
MeSH terms: Crizotinib, Anaplastic Lymphoma Kinase, Adult, Aged, 80 and over, Animals, Antineoplastic Agents, Carbazoles, Carcinoma, Non-Small-Cell Lung, Female, Follow-Up Studies, Humans, Lung Neoplasms, Male, Middle Aged, Piperidines, Pyrazoles, Pyridines, Central Nervous System Neoplasms, Disease-Free Survival, Receptor Protein-Tyrosine Kinases, Protein Kinase Inhibitors, Kaplan-Meier Estimate, Young Adult, Intention to Treat Analysis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Alectinib versus Crizotinib in Untreated ALK -Positive Non–Small-Cell Lung Cancer

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks